Evidence map›Paper›PMID 29067960›Full record

ReviewChinese medical journal2017

Relationship between Apolipoprotein Superfamily and Parkinson's Disease.

Lin Li, Ming-Su Liu, Guang-Qin Li, Jie Tang, Yan Liao, Yang Zheng, Tong-Li Guo, Xin Kang, Mao-Ting Yuan

Open access · goldAbstract readReview
In one paragraph

Review in Chinese medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. PEBP1 inhibition as a therapeutic target for neurological recovery in ischemic stroke.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lin LiDepartment of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Ming-Su LiuDepartment of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Guang-Qin LiDepartment of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Jie TangDepartment of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Yan LiaoDepartment of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Yang ZhengDepartment of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Tong-Li GuoDepartment of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Xin KangDepartment of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Mao-Ting YuanDepartment of Neurology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, China.
Chongqing Medical University · CNFirst Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveParkinson's disease (PD) is featured with motor disorder and nonmotor manifestations including psychological symptoms, autonomic nervous system dysfunction, and paresthesia, which results in great inconvenience to the patients' life. The apolipoprotein (Apo) superfamily, as a group of potentially modifiable biomarkers in clinical practice, is of increasing significance in the diagnosis, evaluation, and prognosis of PD. The present review summarized the current understanding and emerging findings of the relationship between Apo superfamily and PD. DATA SOURCES: All literatures were identified by systematically searching PubMed, Embase, and Cochrane electronic databases with terms "Parkinson disease," "apolipoprotein," and their synonyms until May 2017. STUDY SELECTION: We have thoroughly examined titles and abstracts of all the literatures that met our search strategy and the full text if the research is identified or not so definite. Reference lists of retrieved articles were also scrutinized for additional relevant studies.

resultsThe levels of plasma ApoA1 are inversely correlated with the risk of PD and the lower levels of ApoA1 trend toward association with poorer motor performance. Higher ApoD expression in neurons represents more puissant protection against PD, which is critical in delaying the neurodegeneration process of PD. It is suggested that APOE alleles are related to development and progression of cognitive decline and age of PD onset, but conclusions are not completely identical, which may be attributed to different ApoE isoforms. APOJ gene expressions are upregulated in PD patients and it is possible that high ApoJ level is an indicator of PD dementia and correlates with specific phenotypic variations in PD.

conclusionsThe Apo superfamily has been proved to be closely involved in the initiation, progression, and prognosis of PD. Apos and their genes are of great value in predicting the susceptibility of PD and hopeful to become the target of medical intervention to prevent the onset of PD or slow down the progress. Therefore, further large-scale studies are warranted to elucidate the precise mechanisms of Apos in PD.

Indexed as

Apolipoprotein A-IApolipoproteinsDementiaFemaleHumansMaleParkinson DiseaseAPOA1 protein, humanApolipoprotein A-IApolipoproteins

Identifiers

PMID29067960
PMCPMC5678263
OpenAlexW2765570946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.